Humacyte Future Growth
Future criteria checks 5/6
Humacyte is forecast to grow earnings and revenue by 69% and 72.2% per annum respectively while EPS is expected to grow by 68.6% per annum.
Key information
69.0%
Earnings growth rate
68.6%
EPS growth rate
| Biotechs earnings growth | 27.6% |
| Revenue growth rate | 72.2% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 23 Dec 2024 |
Recent future growth updates
Recent updates
Humacyte's Symvess Debut: A Milestone With Lingering Concerns (Rating Downgrade)
Dec 23Humacyte: FDA Waiting Game Bleeding Company Dry
Dec 14Humacyte: Navigating The FDA Uncertainty And ATEV's Potential
Sep 24Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?
Aug 16
Humacyte: Pioneering Vascular Solutions With High-Stakes Potential
Jul 17Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation
Jun 05Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High
May 14Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?
Feb 14Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 124 | -20 | 63 | 194 | 6 |
| 12/31/2025 | 12 | -110 | -60 | -104 | 7 |
| 12/31/2024 | 0 | -159 | -148 | -109 | 7 |
| 9/30/2024 | N/A | -153 | -92 | -91 | N/A |
| 6/30/2024 | N/A | -140 | -82 | -81 | N/A |
| 3/31/2024 | N/A | -106 | -84 | -82 | N/A |
| 12/31/2023 | N/A | -111 | -76 | -73 | N/A |
| 9/30/2023 | N/A | -89 | -76 | -73 | N/A |
| 6/30/2023 | 0 | -89 | -80 | -77 | N/A |
| 3/31/2023 | 1 | -29 | -73 | -71 | N/A |
| 12/31/2022 | 2 | -12 | -72 | -71 | N/A |
| 9/30/2022 | 2 | 34 | -74 | -74 | N/A |
| 6/30/2022 | 2 | 28 | -88 | -87 | N/A |
| 3/31/2022 | 1 | -26 | -86 | -85 | N/A |
| 12/31/2021 | 1 | -26 | -81 | -81 | N/A |
| 9/30/2021 | 1 | -85 | -75 | -75 | N/A |
| 6/30/2021 | 2 | -71 | -57 | -57 | N/A |
| 3/31/2021 | 1 | -69 | -54 | -54 | N/A |
| 12/31/2020 | 1 | -67 | -56 | -56 | N/A |
| 12/31/2019 | 6 | -85 | -80 | -72 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HUMA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: HUMA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: HUMA is expected to become profitable in the next 3 years.
Revenue vs Market: HUMA's revenue (72.2% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: HUMA's revenue (72.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if HUMA's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 21:27 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Humacyte, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bruce Jackson | Benchmark Company |
| Michael Gorman | BTIG |
| Kristen Kluska | Cantor Fitzgerald & Co. |